Accelero Signs Service Agreement for AAV-Based Gene Therapy Development
Berlin, 21 October 2019
Accelero Bioanalytics GmbH (“Accelero”) signed an agreement with the gene therapy company CombiGene AB, Lund, Sweden (“CombiGene”) to support the non-clinical development of an Adeno-associated virus (AAV) with its bioanalytical and regulatory expertise.
Accelero Sustaining Member of the CONELIS Competence Network Life Science
Berlin, 27 September 2019
Accelero is pleased to announce that the company has been selected as a sustaining member of the CONELIS network life science. The CONELIS network accumulates top-class consulting services for the biotechnology and pharmaceutical industry.
Accelero Participates in TRAIN-HEART Marie Curie Program Discovering RNA Therapeutics for Heart Failure
Berlin, 04 June 2019
Accelero is pleased to announce that the company participates as a partner organization in the Marie Curie TRAIN-HEART consortium funded by the European Commission.
GLP Certificate Refreshed on 15 March 2019
Accelero Bioanalytics GmbH, a Berlin-based GLP certified bioanalytical service provider, announces today that the GLP certificate first issued in 2016 has now been renewed by the competent authority for another three years. The re-inspection has been conducted in November 2018.
